Funding information:

The steroid assessment tool was developed in collaboration with 15 gastroenterologists from the UK and AbbVie, as part of the Treating Beyond Symptoms in IBD quality improvement programme, of which AbbVie is the sole sponsor and provided funding to invited participants, including honoraria for their attendance at the development meetings. Abbvie provided funding for the audit via an unrestricted grant and funding for the development of the steroid assessment web tool, which was developed by Incuna. AbbVie was not involved in the conduct and analysis of the audit, nor the development or review of the manuscript with the authors. This manuscript reflects the opinions of the authors. The authors determined the final content, and all authors read and approved the final manuscript. No payments were made to the authors for the development of this manuscript.